Intra-Cellular Therapies, Inc. v. The Controller of Patents

Relevant Acts and provisions

Patents Act, 1970

Section 2(1)(j)Section 2(1)(ja)Section 3(d)

Provisions considered: Sections 2(1)(j), 2(1)(ja) and 3(d) of the Patents Act, 1970 (as amended).

Brief facts

The Appellant applied for a patent for an invention titled 'ORGANIC COMPOUNDS', involving specific deuterated versions of chemical structures called heterocycle-fused gamma-carbolines, designed for the treatment of diseases involving receptor signalling systems in the brain (such as the 5-HT2A, SERT and dopamine receptors). The Appellant argued that the invention was a significant improvement because in a study the deuterated version stayed in the blood much longer (providing 72% higher parent drug exposure) and produced less of a byproduct called Metabolite X compared with the original, non-deuterated drug. The Controller rejected the application, ruling that it was a mere derivative of known substances and lacked novelty and inventive step based on earlier patents D1 and D7.

Issues before the Court

1. Does the claimed deuterated compound qualify as a 'new product' or is it a mere derivative disclosed in prior art?
2. Is an increase in the amount of intact drug in the blood (higher parent exposure) enough to satisfy the requirement of enhanced therapeutic efficacy under Section 3(d)?

Court's findings

The Court clarified that deuteration, replacing hydrogen atoms with deuterium, is a known technique used to slow down how fast the body breaks down a drug. It observed that while the Appellant showed that its version produced less of a specific byproduct (Metabolite X), it also had to prove that this change actually led to a better medical outcome for the patient. It was noted that if two compounds have similar binding strengths to their targets (pharmacological activity), a longer-lasting presence in the blood may not be enough to justify a new patent if the core function remains the same.

Decision

The Court upheld the Controller's objection under Section 3(d), holding that the Appellant had failed to establish enhanced therapeutic efficacy and was therefore unable to overcome the statutory prohibition under Section 3(d) of the Patents Act, 1970.

Cases cited

• Novartis AG v. Union of India & Ors., (2013) 6 SCC 1

Authorities referred to in the decision. Please verify each citation in the judgment itself.

Keywords

Deuterated Compounds Heterocycle-fused Gamma-carbolines Parent Drug Exposure Pharmacological Activity Section 3(d) Therapeutic Efficacy